Veterinary Molecular Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Veterinary Molecular Diagnostics Market Trends and Insights

Rise in Prevalence of Animal Infectious Diseases

High-pathogenicity avian influenza H5N1 infected U.S. dairy cattle in 2024, pushing laboratories such as the University of Minnesota to process more than 115,000 samples by May 2025. Such surges spur demand for high-throughput PCR platforms that deliver hundreds of results per day and drive adoption of whole-genome sequencing to track viral evolution. Confirmed human H5N1 cases linked to cattle reinforce the One-Health imperative, making molecular diagnostics essential infrastructure for joint animal–human outbreak response. Investments in sequencing capacity therefore shift the veterinary molecular diagnostics market toward integrated, rapid and scalable solutions.

Growing Demand for Animal-Derived Proteins

Rising meat and dairy consumption in Asia Pacific is pushing producers to intensify biosecurity and select disease-resistant genetics. Livestock operators now deploy high-resolution melting assays to distinguish pathogen strains and apply genetic markers for superior feed conversion, cutting antibiotic usage while protecting welfare. This production-oriented testing sustains long-term sales of multiplex platforms capable of combining pathogen detection with genetic profiling inside a single workflow.

Increasing Companion-Animal Ownership & Spend

Eighty percent of pet owners in the United States visit a veterinarian within six months, and willingness to pay for advanced diagnostics is rising. Liquid biopsies, hereditary disease panels, and AI-enabled interpretation tools such as Mars Petcare’s chronic-kidney-disease predictor broaden routine wellness portfolios. Portable analyzers delivering laboratory-quality PCR results during a single clinic visit enhance customer satisfaction and push the veterinary molecular diagnostics market deeper into first-opinion settings.

Adoption of Syndromic Multiplex Panels

Clinical signs often originate from multiple pathogens, making single-plex tests inefficient. Platforms like QIAGEN’s QIAstat-Dx detect up to 12 genomic targets and report within 30 minutes, while including resistance markers that guide antibiotic stewardship. Alveo Technologies’ poultry avian influenza cartridge reaches 99% specificity and uploads results in real time, showing how modular microfluidics reshape biosecurity programs.

One-Health AMR Surveillance Funding Surge

WHO’s antimicrobial-resistance research agenda highlights rapid point-of-care tests as a top priority. The European Union cut antimicrobial use in food animals by 28.3% from 2018-2022, creating a regulatory pull for fast resistance-gene assays. bioMérieux devotes 75% of R&D to AMR solutions, underscoring the commercial importance of integrated panels that detect pathogens and resistance determinants in a single run.

Portable Nanopore Sequencing Enters Field Use

Oxford Nanopore’s MinION delivers real-time genomic reads in barns and remote clinics, enabling on-site avian-influenza surveillance without costly sample transport. Direct RNA sequencing and ultra-long reads let veterinarians characterize complex viral genomes and monitor mutations immediately, widening access in developing regions with minimal laboratory infrastructure.

Lack of Skilled Veterinary Molecular Diagnosticians

Vacancy rates for laboratory technologists have reached 35%-40% in human health, with parallel gaps in veterinary practice. Rural veterinarians must often double as lab technicians, yet most veterinary curricula provide limited molecular-biology training. Staffing shortages slow installation of advanced platforms and limit the veterinary molecular diagnostics market in smaller clinics.

High Cost of Instruments & Consumables

Comprehensive PCR or sequencing systems frequently exceed USD 100,000, while per-test consumable costs run 3-5 times higher than conventional assays. Financial pressure is acute for stand-alone practices and rural clinics, causing a two-tier market where sophisticated testing concentrates in corporate chains and reference laboratories.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Kits Drive Revenue, Software Accelerates Growth

Kits and reagents produced 58.50% of 2025 revenues, anchoring a recurring business model that stabilizes cash flow for suppliers. Software and services, however, are expanding at an 11.7% CAGR as cloud analytics, AI interpretive modules, and subscription data portals become integral to laboratory operations. Leading vendors bundle consumables, instruments, and analytics, reinforcing switching barriers. The veterinary molecular diagnostics market size attributable to consumables is forecast to remain dominant through 2031, yet software will command increasing strategic importance for differentiation. Instrument margins tighten as miniaturization and open-platform designs lower entry barriers, illustrated by portable nanopore sequencers costing a fraction of legacy bench-top systems. As a result, manufacturers pivot toward integrated ecosystems that pair hardware with digital interpretation and lifetime kit revenue.

By Application: Infectious Diseases Dominate, Genetics Gains Momentum

Infectious disease surveillance generated 68.90% of 2025 sales and remains the core of the veterinary molecular diagnostics market as laboratories manage avian influenza, African swine fever, and canine parvovirus. Syndromic panels shorten differential diagnosis and reduce empirical antibiotic use. Genetics applications, advancing at a 10.24% CAGR, reflect pet owners’ desire for hereditary screening and breeders’ focus on genomic selection. Liquid biopsies for oncology further widen clinical adoption. The veterinary molecular diagnostics market size for genetics is projected to accelerate as sequencing costs fall, enabling routine screening for both disease predisposition and performance traits.

By Technology: PCR Leads, DNA Sequencing Shows Promise

PCR held 61.40% revenue share in 2025 due to robustness, speed, and cost-effectiveness. Innovations such as rapid-cycle chemistry permit sub-hour turnaround, bringing PCR into in-clinic use. DNA sequencing, projected to grow 13.6% annually, extends beyond confirmatory testing into frontline diagnostics, especially as nanopore formats make field deployment practical. The convergence of PCR amplification with on-chip sequencing workflows blurs traditional boundaries and could reshape the veterinary molecular diagnostics market by delivering both qualitative and quantitative insights in one platform.

By Animal Type: Companion Animals Drive Innovation

 Companion animals dominated with a 64.45% 2025 revenue share, whereas livestock testing for poultry and cattle is forecast to grow the quickest at 11.12% CAGR over the same period. Companion animals generate the largest spending as owners seek human-level care, including AI-guided interpretation of molecular results. Predictive analytics for chronic kidney disease and oncology screening expand the service mix at veterinary hospitals. Livestock testing grows strongly in poultry and dairy cattle, where proactive surveillance underpins productivity and food safety. Precision selection based on molecular markers reduces antibiotic inputs and aligns with One-Health goals, reinforcing the veterinary molecular diagnostics industry’s relevance to public health.

By End User: Reference Labs Lead, Clinics Embrace Point-of-Care

Reference laboratories led the market with a 67.40% share in 2025; clinics are adopting point-of-care systems at the fastest pace, at 12.16% CAGR over the same period. Reference laboratories dominate high-complexity testing through economies of scale, supporting next-generation sequencing and bespoke pathogen panels. Yet, clinics are the fastest-growing users as cartridge-based PCR systems and portable sequencers deliver definitive results during appointments. This decentralisation increases testing volumes and feeds cloud databases that power AI benchmarking, deepening customer reliance on integrated vendor ecosystems.

Geography Analysis

North America captured 41.20% revenue in 2025, underpinned by extensive veterinary infrastructure, generous pet-care spending, and USDA funding of USD 64.429 million for animal-health diagnostics in 2025. Federal fast-track pathways for new assays accelerate innovation, though rural skills shortages remain a bottleneck.

Europe maintains a substantial share thanks to strict antimicrobial stewardship rules. Regulation (EU) 2019/6 modernizes veterinary medicinal oversight and boosts demand for rapid resistance testing. Between 2018 and 2022, the region cut antimicrobial use in food animals by 28.3%, prompting farms to adopt molecular surveillance as a compliance tool.

Asia Pacific is the fastest-growing territory at an 10.96% CAGR. Middle-class pet ownership, mega-dairy expansion, and supportive policies such as the ASEAN Medical Device Directive spur uptake. Latin America and the Middle East & Africa record steady adoption, although currency volatility and limited laboratory networks temper growth. Portable diagnostic kits tailored for diverse species and climates show promise for accelerating penetration in these regions.

Regulatory Landscape

Regulation in veterinary molecular diagnostics remains fragmented by jurisdiction, and official disease-control programs often determine the practical pathway for assay use. In the United States, USDA APHIS oversight is central for assays used in official testing, including expectations for licensed diagnostic test kits and APHIS-approved laboratories operating under prescribed methods and proficiency practices (with requirements referenced through APHIS guidance and 9 CFR provisions for approved testing). This structure supports standardized surveillance workflows for high-consequence diseases and tends to steer procurement toward validated, program-aligned PCR and sequencing solutions.

Across Europe, veterinary IVDs do not fall under the same harmonized device legislation used for human IVDs (Regulation (EU) 2017/746 is human-focused), so manufacturer compliance requirements remain more country-specific. Standardization efforts are advancing through formal standards: CEN published EN 18000-1:2026 and EN 18000-2:2026, which set requirements around application files and batch-to-batch quality controls for animal-health IVD reagents. In Australia, NATA made its Animal Health ISO/IEC 17025 appendix effective in February 2026, reinforcing laboratory controls such as physical separation of pre- and post-amplification areas for nucleic-acid testing, and raising quality-system expectations for accredited veterinary molecular laboratories.

Value Chain Analysis

The value chain runs from upstream suppliers of enzymes, primers/probes, plastics, and microfluidic components through assay design and validation, kit manufacturing, instrument production, and distribution to reference laboratories, veterinary hospitals and clinics, and on-farm users. A defining characteristic is dependence on specialized consumables and imported reagents in many regions, which increases exposure to lead times and single-source risk for critical inputs such as polymerases and fluorescent chemistries. Validation, quality control, and documentation are tightly coupled to downstream adoption because reference labs and official testing programs require standardized performance, pushing suppliers to provide complete workflows (sample prep, reagents, controls, software) rather than standalone components.

Downstream, sample logistics and workflow support are pivotal. Reference labs capture high-complexity volumes, while field-deployable isothermal PCR and portable sequencing expand access where transport and infrastructure constraints disrupt sample integrity and instrument uptime. Distribution partnerships increasingly bridge technology developers and animal-health channels, illustrated by Enalees announcing a strategic distribution agreement with Unisensor in March 2026 to broaden reach of its Rhéa rapid isothermal PCR tests across European and North American livestock markets. Regulatory and oversight touchpoints also shape the chain, including USDA APHIS laboratory approval requirements and the clarified USDA-FDA oversight framework for animal biologicals, which influence how companies structure labeling, validation packages, and go-to-market routes for diagnostics used in surveillance and control programs.

Market Opportunities and Future Outlook

White space is expanding for molecular platforms that shorten time-to-action during outbreaks while also fitting routine precision-medicine workflows for companion animals. Capacity pressure from high-consequence disease testing has already been demonstrated, such as the University of Minnesota processing more than 115,000 H5N1-related samples by May 2025, which reinforces demand for scalable PCR and sequencing that can be deployed across networks. One route to absorb these volumes is centralized, logistics-optimized reference testing, highlighted by Zoetis opening a 32,000-square-foot reference laboratory at the UPS Healthcare Labport in Louisville, Kentucky (May 2025), linking high-throughput molecular work with overnight specimen movement and faster reporting.

A second opportunity area is newer modalities and automation that broaden what can be tested and where. In 2025, Oxford Nanopore Technologies introduced the ElysION workstation to automate end-to-end sequencing workflows, reducing manual steps that often constrain adoption in veterinary labs with staffing constraints. On the assay-expansion side, NGS and novel assay chemistries are moving into focused veterinary use cases: MiDOG Animal Diagnostics launched MiDOG Parasite-Only Testing in July 2026 as a dedicated NGS-based parasite detection offering. Published research also continues to validate CRISPR-based and hybrid approaches for rapid pathogen detection in livestock syndromes, including diarrhea panels. Together, these developments point to opportunities for vendors that pair assays with curated genomic databases, cloud reporting, and training to address multi-species validation gaps and operational bottlenecks in decentralized testing.